PMA

P160038: Praxis Extended RAS Panel

FDA PMA · Next generation sequencing oncology panel, somatic or germline variant detection system · Illumina, Inc.

Key facts

PMA number P160038
Trade name Praxis Extended RAS Panel
Generic name Next generation sequencing oncology panel, somatic or germline variant detection system
Applicant Illumina, Inc.
Owner/operator Illumina, Inc.
Product code PQP
Approval date Jun 29, 2017
Docket number 17M-3983
Notice date Jun 30, 2017
Establishment registration 3003218906
FEI number 3003218906

At a glance

  • 10–99 Supplements
  • Feb 17, 2023 Latest supplement decision
  • No Withdrawn
  • Yes Summary of safety and effectiveness on file
  • 1–9 UDI device identifiers (GUDID)
  • None MAUDE adverse event reports
  • None Recall events

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMA approvals

Premarket approval (PMA) is the FDA's most stringent review pathway, required for most Class III devices that support or sustain life or present a potentially unreasonable risk.

Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date:

Browse all PMA approvals